<DOC>
	<DOCNO>NCT00263185</DOCNO>
	<brief_summary>The purpose study determine whether Vitamin D supplementation reduces symptoms muscle stiffness joint tenderness patient may develop start therapy Anastrozole breast cancer .</brief_summary>
	<brief_title>High Dose Vit D Musculoskeletal Symptoms &amp; Bone Density Anastrozole-Treated Breast Cancer With Marginal Vit D Status</brief_title>
	<detailed_description>This pilot , double-blind , randomize , placebo-controlled study follow aim : - To compare effect high dose vitamin D versus standard dose vitamin D musculoskeletal pain breast cancer patient receive anastrozole vitamin D level insufficient deficient range ( 10 29 ng/ml ) . - To evaluate prevalence vitamin D insufficiency/deficiency post-menopausal woman history breast cancer treat anastrozole musculoskeletal symptom versus asymptomatic . - To establish correlation level vitamin D , level PTH , degree bone loss severity musculoskeletal symptom . - To evaluate effect standard dose versus high dose Vitamin D replacement bone density post-menopausal woman history breast cancer treat anastrozole musculoskeletal symptom .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Inclusion Criteria Women diagnosis hormone receptor positive invasive breast cancer ( Stage IIIIB ) ductal carcinoma situ ( DCIS ) Postmenopausal status Completed least 8 week anastrozole adjuvant therapy prior study entry Completed systemic chemotherapy radiation treatment indicate Serum Calcium ≤ 10.3 mg/dL Patients marginal 25 OH Vitamin D level ( 10 29 ng/ml ) Randomized Group Low 25 OH Vitamin D level ( le 10 ng/ml ) Observational Group 24hour urine Calcium excretion ≤ 250 mg/g ( calculate divide 24 hour calcium 24 hour creatinine ) A history generalize musculoskeletal pain without localized region discomfort develop worsen since start adjuvant aromatase inhibitor therapy Exclusion Criteria Known metastatic disease History kidney stone History active primary hyperparathyroidism History Paget 's disease bone History severe arthritis , rheumatoid arthritis , severe neuropathy Normal 25 OH Vitamin D level ( ≥ 30 ng/ml ) Medical psychiatric condition may preclude protocol compliance</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>